Marshall Wace LLP Invests $457,000 in REGENXBIO Inc. (NASDAQ:RGNX)

Marshall Wace LLP bought a new stake in REGENXBIO Inc. (NASDAQ:RGNX) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 39,093 shares of the biotechnology company’s stock, valued at approximately $457,000. Marshall Wace LLP owned 0.08% of REGENXBIO at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. PNC Financial Services Group Inc. raised its position in REGENXBIO by 73.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 1,761 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 746 shares in the last quarter. ProShare Advisors LLC raised its holdings in REGENXBIO by 8.3% in the first quarter. ProShare Advisors LLC now owns 11,384 shares of the biotechnology company’s stock valued at $240,000 after acquiring an additional 874 shares in the last quarter. Maryland State Retirement & Pension System lifted its stake in REGENXBIO by 7.2% in the second quarter. Maryland State Retirement & Pension System now owns 15,800 shares of the biotechnology company’s stock worth $185,000 after acquiring an additional 1,067 shares during the last quarter. Amalgamated Bank grew its holdings in REGENXBIO by 9.9% during the 2nd quarter. Amalgamated Bank now owns 13,613 shares of the biotechnology company’s stock worth $159,000 after acquiring an additional 1,227 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its holdings in REGENXBIO by 8.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 18,177 shares of the biotechnology company’s stock worth $383,000 after acquiring an additional 1,438 shares in the last quarter. 88.08% of the stock is owned by institutional investors and hedge funds.

REGENXBIO Price Performance

Shares of REGENXBIO stock opened at $9.29 on Friday. The firm’s fifty day simple moving average is $11.57 and its 200-day simple moving average is $13.86. REGENXBIO Inc. has a 12 month low of $9.11 and a 12 month high of $28.80. The stock has a market capitalization of $459.11 million, a price-to-earnings ratio of -1.58 and a beta of 1.21.

REGENXBIO (NASDAQ:RGNX) last announced its earnings results on Thursday, August 1st. The biotechnology company reported ($1.05) EPS for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.24. REGENXBIO had a negative net margin of 270.74% and a negative return on equity of 68.21%. The business had revenue of $22.30 million during the quarter, compared to analysts’ expectations of $22.97 million. During the same period in the prior year, the company earned ($1.66) earnings per share. The business’s revenue was up 11.6% compared to the same quarter last year. Analysts anticipate that REGENXBIO Inc. will post -4.66 earnings per share for the current year.

Analyst Upgrades and Downgrades

RGNX has been the subject of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $39.00 price objective on shares of REGENXBIO in a research report on Wednesday, September 4th. Barclays lowered their price objective on REGENXBIO from $55.00 to $50.00 and set an “overweight” rating for the company in a research report on Monday, August 5th. Raymond James reissued an “outperform” rating and set a $18.00 target price on shares of REGENXBIO in a research report on Thursday. Finally, StockNews.com raised REGENXBIO from a “sell” rating to a “hold” rating in a report on Friday, September 20th. Three equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $35.45.

Insiders Place Their Bets

In other news, Director Kenneth T. Mills sold 12,221 shares of the business’s stock in a transaction that occurred on Wednesday, July 24th. The stock was sold at an average price of $13.78, for a total value of $168,405.38. Following the transaction, the director now owns 408,035 shares of the company’s stock, valued at approximately $5,622,722.30. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, Director Argeris N. Karabelas sold 11,000 shares of the stock in a transaction dated Monday, July 29th. The shares were sold at an average price of $15.04, for a total transaction of $165,440.00. Following the completion of the transaction, the director now directly owns 11,286 shares of the company’s stock, valued at $169,741.44. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Kenneth T. Mills sold 12,221 shares of REGENXBIO stock in a transaction that occurred on Wednesday, July 24th. The shares were sold at an average price of $13.78, for a total value of $168,405.38. Following the completion of the sale, the director now directly owns 408,035 shares in the company, valued at $5,622,722.30. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 65,279 shares of company stock valued at $864,034. 13.13% of the stock is owned by company insiders.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.